샘플 요청 목록

 카트 문의
시장보고서
상품코드
1786884

임상 종양학 차세대 시퀀싱 시장 : 규모, 점유율, 동향, 산업 분석 보고서 - 기술별, 워크 플로우별, 용도별, 최종 용도별, 지역별, 시장 예측(2025-2034년)

Clinical Oncology Next Generation Sequencing Market Size, Share, Trends, Industry Analysis Report By Technology (Whole Genome Sequencing, Whole Exome Sequencing), By Workflow, By Application, By End Use, By Region - Market Forecast, 2025-2034
발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 129 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면 임상 종양학 차세대 시퀀싱(NGS) 시장 규모는 2034년까지 22억 879만 달러에 이를 전망입니다. 이 설문조사 보고서는 현재 시장 역학을 자세히 파악하고 향후 시장 성장에 대한 분석을 제공합니다.

임상 종양학 차세대 시퀀싱(NGS)은 종양 DNA와 RNA의 종합적인 분석을 가능하게 하는 고처리량 유전체 기술로, 암을 촉진하는 돌연변이, 카피수의 돌연변이, 유전자 융합, 기타 분자 변화를 동정합니다. 이 기술은 임상의가 실용적인 분자 표적을 확인하고 치료 반응을 예측하고 전례 없는 정확도로 질병 진행을 모니터링할 수 있게 함으로써 Precision On Collogy에 혁명을 일으킵니다.

차세대 시퀀싱은 신규 바이오마커를 동정하고 유전자형을 매치시킨 임상시험에 환자를 등록함으로써 암 연구를 촉진합니다. 그 변화의 가능성에도 불구하고, 이 기술은 종양 불균일성, 데이터 분석의 복잡성, 비용 장벽 등의 과제에 직면하고 있습니다. 그러나 싱글셀 시퀀싱, 롱리드 기술, 인공지능의 발전으로 NGS의 정확성과 접근성이 향상되어 시장 성장의 원동력이 되고 있습니다.

임상 종양학 차세대 시퀀싱 시장 보고서 하이라이트

기술적 측면에서 타겟 시퀀싱 및 리시퀀싱 부문은 비용 효과, 커버리지 깊이 높이, 특정 유전자 또는 유전체 영역에 초점을 맞추는 능력에 의해 2024년 시장 수익 점유율의 64.93%를 차지했습니다.

워크 플로우별로는 암 유전체를 고정밀도로 해석할 수 있는 고처리량, 고정밀도, 고비용 효율의 플랫폼에 대한 수요의 급증에 의해 시퀀싱 부문이 2024년 시장 매출 점유율의 57.03%를 차지했습니다.

용도별로, 동반진단약 분야가 2024년에 71.83%의 매출 점유율을 획득하여 시장을 선도했습니다. 이 이점은 관련 유전자 바이오마커를 가진 FDA 승인 항암제의 수가 증가하고 있기 때문입니다.

최종 용도별로는 분산형 검사나 POC(Point of Care) 진단으로의 시프트에 의해 클리닉 분야가 향후 수년간에 CAGR 19.21%를 보일 것으로 예측되고 있습니다.

2024년 세계의 임상 종양학 차세대 시퀀싱(NGS) 시장에서는 북미가 44.16%의 점유율을 차지했습니다. 이 이점은 높은 암 유병률, 고급 헬스케어 인프라, 정밀의료의 강력한 도입으로 인해 발생합니다.

유럽 시장은 암 환자 증가, 정부 지원 정책, 유전체 의료 투자 증가로 2034년 상당한 시장 점유율을 차지할 것으로 예측됩니다.

아시아태평양 시장은 예측 기간 동안 가장 높은 CAGR을 나타낼 것으로 예측됩니다. 이는 암 부담 증가, 헬스케어 접근 개선, 유전체 의료 투자 증가로 인한 것입니다.

세계 주요 시장 기업으로는 Agilent Technologies, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Illumina, Inc., Myriad Genetics, Oxford Nanopore Technologies Ltd., Pacific Bioscience, Perkin Elmer, Qiagen NV, Thermo Fisher Scientific 등이 있습니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 임상 종양학 차세대 시퀀싱 시장 인사이트

  • 시장 현황
  • 임상 종양학 차세대 시퀀싱 시장 역학
    • 성장 촉진요인 및 기회
      • 기술 진보의 가속
      • 헬스케어 비용 증가
    • 성장 억제요인 및 과제
      • 고비용
  • PESTEL 분석
  • 임상 종양학 차세대 시퀀싱 시장 동향
  • 밸류체인 분석

제5장 세계의 임상 종양학 차세대 시퀀싱 시장 : 기술별

  • 주요 조사 결과
  • 서문
  • 전체 유전체 서열 분석
  • 모든 엑솜 시퀀싱
  • 타겟 시퀀싱과 리시퀀싱

제6장 세계의 임상 종양학 차세대 시퀀싱 시장 : 용도별

  • 주요 조사 결과
  • 서문
  • 스크리닝
  • 동반진단
  • 기타

제7장 세계의 임상 종양학 차세대 시퀀싱 시장 : 워크 플로우별

  • 주요 조사 결과
  • 서문
  • 사전 시퀀싱
  • 시퀀싱
  • 데이터 분석

제8장 세계의 임상 종양학 차세대 시퀀싱 시장 : 최종 용도별

  • 주요 조사 결과
  • 서문
  • 병원
  • 클리닉
  • 기타

제9장 세계의 임상 종양학 차세대 시퀀싱 시장 : 지역별

  • 주요 조사 결과
  • 서문
    • 임상 종양학 차세대 시퀀싱 시장 평가 : 지역별(2020-2034년)
  • 북미
    • 북미 : 기술별(2020-2034년)
    • 북미 : 용도별(2020-2034년)
    • 북미 : 워크 플로우별(2020-2034년)
    • 북미 : 최종 용도별(2020-2034년)
    • 미국
    • 캐나다
  • 유럽
    • 유럽 : 기술별(2020-2034년)
    • 유럽 : 용도별(2020-2034년)
    • 유럽 : 워크 플로우별(2020-2034년)
    • 유럽 : 최종 용도별(2020-2034년)
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
    • 기타 유럽
  • 아시아태평양
    • 아시아태평양 : 기술별(2020-2034년)
    • 아시아태평양 : 용도별(2020-2034년)
    • 아시아태평양 : 워크 플로우별(2020-2034년)
    • 아시아태평양 : 최종 용도별(2020-2034년)
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
    • 호주
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 중동 및 아프리카 : 기술별(2020-2034년)
    • 중동 및 아프리카 : 용도별(2020-2034년)
    • 중동 및 아프리카 : 워크 플로우별(2020-2034년)
    • 중동 및 아프리카 : 최종 용도별(2020-2034년)
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 남아프리카
    • 기타 중동 및 아프리카
  • 라틴아메리카
    • 라틴아메리카 : 기술별(2020-2034년)
    • 라틴아메리카 : 용도별(2020-2034년)
    • 라틴아메리카 : 워크 플로우별(2020-2034년)
    • 라틴아메리카 : 최종 용도별(2020-2034년)
    • 멕시코
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카

제10장 경쟁 구도

  • 확대 및 인수 분석
    • 확대
    • 인수
  • 제휴, 협업, 합의 및 공개

제11장 기업 프로파일

  • Agilent Technologies
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Myriad Genetics
  • Oxford Nanopore Technologies Ltd.
  • Pacific Bioscience
  • Perkin Elmer
  • Qiagen NV
  • Thermo Fisher Scientific
AJY 25.08.18

The Clinical oncology next generation sequencing (NGS) market size is expected to reach USD 2,208.79 million by 2034, according to a new study by Polaris Market Research. The report "Clinical Oncology Next Generation Sequencing Market Share, Size, Trends, Industry Analysis Report By Technology (Whole Genome Sequencing, Whole Exome Sequencing), By Workflow, By Application, By End Use, By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Clinical oncology next generation sequencing (NGS) is a high-throughput genomic technology that enables comprehensive analysis of tumor DNA and RNA to identify cancer-driving mutations, copy number variations, gene fusions, and other molecular alterations. This technology is revolutionizing precision oncology by allowing clinicians to identify actionable molecular targets, predict treatment responses, and monitor disease progression with unprecedented accuracy.

Next generation sequencing fuels cancer research by identifying novel biomarkers and enrolling patients in genotype-matched clinical trials. Despite its transformative potential, the technology faces challenges such as tumor heterogeneity, data interpretation complexity, and cost barriers. However, advancements in single-cell sequencing, long-read technologies, and artificial intelligence are enhancing NGS accuracy and accessibility, driving market growth.

Clinical Oncology Next Generation Sequencing Market Report Highlights

In terms of technology, the targeted sequencing & resequencing segment accounted for 64.93% of market revenue share in 2024 due to its cost-effectiveness, high depth of coverage, and ability to focus on specific genes or genomic regions.

Based on workflow, the sequencing segment held 57.03% of market revenue share in 2024 due to a surge in demand for high-throughput, accurate, and cost-efficient platforms capable of analyzing cancer genomes with increased precision.

In terms of application, the companion diagnostics segment led the market in 2024 by capturing 71.83% revenue share. This dominance is attributed to the rising number of FDA-approved cancer drugs with associated genetic biomarkers.

Based on end use, the clinics segment is projected to register a CAGR of 19.21% in the coming years, owing to the shift toward decentralized testing and point-of-care diagnostics.

North America accounted for a 44.16% share of the global clinical oncology next generation sequencing (NGS) market in 2024. This dominance is attributed to the high prevalence of cancer, advanced healthcare infrastructure, and strong adoption of precision medicine.

The market in Europe is projected to hold a substantial market share in 2034, owing to increasing cancer cases, supportive government policies, and rising investments in genomic medicine.

The market in Asia Pacific is expected to register the highest CAGR during the forecast period, owing to the rising cancer burden, improving healthcare access, and increasing investments in genomics.

A few global key market players include Agilent Technologies; Eurofins Scientific S.E.; F. Hoffmann-La Roche Ltd.; Illumina, Inc.; Myriad Genetics; Oxford Nanopore Technologies Ltd.; Pacific Bioscience; Perkin Elmer; Qiagen N.V.; and Thermo Fisher Scientific.

Polaris Market Research has segmented the clinical oncology next generation sequencing market report on the basis of technology, workflow, application, end use, and region:

By Technology Outlook (Revenue, USD Million, 2020-2034)

Whole Genome Sequencing

Whole Exome Sequencing

Targeted Sequencing & Resequencing

By Workflow Outlook (Revenue, USD Million, 2020-2034)

Pre-Sequencing

Sequencing

Data Analysis

By Application Outlook (Revenue, USD Million, 2020-2034)

Screening

Sporadic Cancer

Inherited Cancer

Companion Diagnostics

Other

By End Use Outlook (Revenue, USD Million, 2020-2034)

Hospitals

Clinics

Laboratories

By Regional Outlook (Revenue, USD Million, 2020-2034)

North America

U.S.

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Source
    • 3.2.1. Primary Source
    • 3.2.2. Secondary Source

4. Global Clinical Oncology Next Generation Sequencing Market Insights

  • 4.1. Clinical Oncology Next Generation Sequencing Market - Market Snapshot
  • 4.2. Clinical Oncology Next Generation Sequencing Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Technological Advancements,
      • 4.2.1.2. Rising Healthcare Spending
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Clinical Oncology Next Generation Sequencing Market Trends
  • 4.6. Value Chain Analysis

5. Global Clinical Oncology Next Generation Sequencing Market, by Technology

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
  • 5.3. Whole Genome Sequencing
    • 5.3.1. Global Clinical Oncology Next Generation Sequencing Market, by Whole Genome Sequencing, by Region, 2020-2034 (USD Million)
  • 5.4. Whole Exome Sequencing
    • 5.4.1. Global Clinical Oncology Next Generation Sequencing Market, by Whole Exome Sequencing, by Region, 2020-2034 (USD Million)
  • 5.5. Targeted Sequencing & Resequencing
    • 5.5.1. Global Clinical Oncology Next Generation Sequencing Market, by Targeted Sequencing & Resequencing, by Region, 2020-2034 (USD Million)

6. Global Clinical Oncology Next Generation Sequencing Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
  • 6.3. Screening
    • 6.3.1. Global Clinical Oncology Next Generation Sequencing Market, by Screening, by Region, 2020-2034 (USD Million)
    • 6.3.2. Sporadic Cancer
      • 6.3.2.1. Global Clinical Oncology Next Generation Sequencing Market, by Sporadic Cancer, by Region, 2020-2034 (USD Million)
    • 6.3.3. Inherited Cancer
      • 6.3.3.1. Global Clinical Oncology Next Generation Sequencing Market, by Inherited Cancer, by Region, 2020-2034 (USD Million)
  • 6.4. Companion Diagnostics
    • 6.4.1. Global Clinical Oncology Next Generation Sequencing Market, by Companion Diagnostics, by Region, 2020-2034 (USD Million)
  • 6.5. Others
    • 6.5.1. Global Clinical Oncology Next Generation Sequencing Market, by Others, by Region, 2020-2034 (USD Million)

7. Global Clinical Oncology Next Generation Sequencing Market, by Workflow

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
  • 7.3. Pre-Sequencing
    • 7.3.1. Global Clinical Oncology Next Generation Sequencing Market, by Pre-Sequencing, by Region, 2020-2034 (USD Million)
  • 7.4. Sequencing
    • 7.4.1. Global Clinical Oncology Next Generation Sequencing Market, by Sequencing, by Region, 2020-2034 (USD Million)
  • 7.5. Data Analysis
    • 7.5.1. Global Clinical Oncology Next Generation Sequencing Market, by Data Analysis, by Region, 2020-2034 (USD Million)

8. Global Clinical Oncology Next Generation Sequencing Market, by End Use

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
  • 8.3. Hospitals
    • 8.3.1. Global Clinical Oncology Next Generation Sequencing Market, by Hospitals, by Region, 2020-2034 (USD Million)
  • 8.4. Clinics
    • 8.4.1. Global Clinical Oncology Next Generation Sequencing Market, by Clinics, by Region, 2020-2034 (USD Million)
  • 8.5. Others
    • 8.5.1. Global Clinical Oncology Next Generation Sequencing Market, by Others, by Region, 2020-2034 (USD Million)

9. Global Clinical Oncology Next Generation Sequencing Market, by Geography

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Clinical Oncology Next Generation Sequencing Market Assessment, By Geography, 2020-2034 (USD Million)
  • 9.3. Clinical Oncology Next Generation Sequencing Market - North America
    • 9.3.1. North America: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
    • 9.3.2. North America: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
    • 9.3.3. North America: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
    • 9.3.4. North America: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.3.5. Clinical Oncology Next Generation Sequencing Market - US
      • 9.3.5.1. US: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.3.5.2. US: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.3.5.3. US: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.3.5.4. US: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.3.6. Clinical Oncology Next Generation Sequencing Market - Canada
      • 9.3.6.1. Canada: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.3.6.2. Canada: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.3.6.3. Canada: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.3.6.4. Canada: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
  • 9.4. Clinical Oncology Next Generation Sequencing Market - Europe
    • 9.4.1. Europe: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
    • 9.4.2. Europe: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
    • 9.4.3. Europe: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
    • 9.4.4. Europe: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.4.5. Clinical Oncology Next Generation Sequencing Market - UK
      • 9.4.5.1. UK: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.4.5.2. UK: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.4.5.3. UK: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.4.5.4. UK: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.4.6. Clinical Oncology Next Generation Sequencing Market - France
      • 9.4.6.1. France: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.4.6.2. France: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.4.6.3. France: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.4.6.4. France: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.4.7. Clinical Oncology Next Generation Sequencing Market - Germany
      • 9.4.7.1. Germany: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.4.7.2. Germany: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.4.7.3. Germany: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.4.7.4. Germany: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.4.8. Clinical Oncology Next Generation Sequencing Market - Italy
      • 9.4.8.1. Italy: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.4.8.2. Italy: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.4.8.3. Italy: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.4.8.4. Italy: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.4.9. Clinical Oncology Next Generation Sequencing Market - Spain
      • 9.4.9.1. Spain: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.4.9.2. Spain: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.4.9.3. Spain: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.4.9.4. Spain: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.4.10. Clinical Oncology Next Generation Sequencing Market - Netherlands
      • 9.4.10.1. Netherlands: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.4.10.2. Netherlands: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.4.10.3. Netherlands: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.4.10.4. Netherlands: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.4.11. Clinical Oncology Next Generation Sequencing Market - Russia
      • 9.4.11.1. Russia: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.4.11.2. Russia: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.4.11.3. Russia: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.4.11.4. Russia: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.4.12. Clinical Oncology Next Generation Sequencing Market - Rest of Europe
      • 9.4.12.1. Rest of Europe: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.4.12.2. Rest of Europe: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.4.12.3. Rest of Europe: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.4.12.4. Rest of Europe: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
  • 9.5. Clinical Oncology Next Generation Sequencing Market - Asia Pacific
    • 9.5.1. Asia Pacific: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
    • 9.5.2. Asia Pacific: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
    • 9.5.3. Asia Pacific: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
    • 9.5.4. Asia Pacific: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.5.5. Clinical Oncology Next Generation Sequencing Market - China
      • 9.5.5.1. China: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.5.5.2. China: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.5.5.3. China: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.5.5.4. China: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.5.6. Clinical Oncology Next Generation Sequencing Market - India
      • 9.5.6.1. India: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.5.6.2. India: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.5.6.3. India: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.5.6.4. India: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.5.7. Clinical Oncology Next Generation Sequencing Market - Malaysia
      • 9.5.7.1. Malaysia: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.5.7.2. Malaysia: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.5.7.3. Malaysia: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.5.7.4. Malaysia: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.5.8. Clinical Oncology Next Generation Sequencing Market - Japan
      • 9.5.8.1. Japan: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.5.8.2. Japan: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.5.8.3. Japan: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.5.8.4. Japan: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.5.9. Clinical Oncology Next Generation Sequencing Market - Indonesia
      • 9.5.9.1. Indonesia: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.5.9.2. Indonesia: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.5.9.3. Indonesia: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.5.9.4. Indonesia: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.5.10. Clinical Oncology Next Generation Sequencing Market - South Korea
      • 9.5.10.1. South Korea: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.5.10.2. South Korea: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.5.10.3. South Korea: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.5.10.4. South Korea: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.5.11. Clinical Oncology Next Generation Sequencing Market - Australia
      • 9.5.11.1. Australia: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.5.11.2. Australia: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.5.11.3. Australia: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.5.11.4. Australia: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.5.12. Clinical Oncology Next Generation Sequencing Market - Rest of Asia Pacific
      • 9.5.12.1. Rest of Asia Pacific: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.5.12.2. Rest of Asia Pacific: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.5.12.3. Rest of Asia Pacific: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.5.12.4. Rest of Asia Pacific: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
  • 9.6. Clinical Oncology Next Generation Sequencing Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
    • 9.6.2. Middle East & Africa: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
    • 9.6.3. Middle East & Africa: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
    • 9.6.4. Middle East & Africa: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.6.5. Clinical Oncology Next Generation Sequencing Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.6.5.2. Saudi Arabia: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.6.5.3. Saudi Arabia: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.6.5.4. Saudi Arabia: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.6.6. Clinical Oncology Next Generation Sequencing Market - UAE
      • 9.6.6.1. UAE: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.6.6.2. UAE: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.6.6.3. UAE: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.6.6.4. UAE: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.6.7. Clinical Oncology Next Generation Sequencing Market - Israel
      • 9.6.7.1. Israel: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.6.7.2. Israel: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.6.7.3. Israel: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.6.7.4. Israel: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.6.8. Clinical Oncology Next Generation Sequencing Market - South Africa
      • 9.6.8.1. South Africa: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.6.8.2. South Africa: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.6.8.3. South Africa: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.6.8.4. South Africa: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.6.9. Clinical Oncology Next Generation Sequencing Market - Rest of Middle East & Africa
      • 9.6.9.1. Rest of Middle East & Africa: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.6.9.2. Rest of Middle East & Africa: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.6.9.3. Rest of Middle East & Africa: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.6.9.4. Rest of Middle East & Africa: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
  • 9.7. Clinical Oncology Next Generation Sequencing Market - Latin America
    • 9.7.1. Latin America: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
    • 9.7.2. Latin America: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
    • 9.7.3. Latin America: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
    • 9.7.4. Latin America: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.7.5. Clinical Oncology Next Generation Sequencing Market - Mexico
      • 9.7.5.1. Mexico: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.7.5.2. Mexico: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.7.5.3. Mexico: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.7.5.4. Mexico: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.7.6. Clinical Oncology Next Generation Sequencing Market - Brazil
      • 9.7.6.1. Brazil: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.7.6.2. Brazil: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.7.6.3. Brazil: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.7.6.4. Brazil: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.7.7. Clinical Oncology Next Generation Sequencing Market - Argentina
      • 9.7.7.1. Argentina: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.7.7.2. Argentina: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.7.7.3. Argentina: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.7.7.4. Argentina: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)
    • 9.7.8. Clinical Oncology Next Generation Sequencing Market - Rest of Latin America
      • 9.7.8.1. Rest of Latin America: Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2034 (USD Million)
      • 9.7.8.2. Rest of Latin America: Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2034 (USD Million)
      • 9.7.8.3. Rest of Latin America: Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2034 (USD Million)
      • 9.7.8.4. Rest of Latin America: Clinical Oncology Next Generation Sequencing Market, by End Use, 2020-2034 (USD Million)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Agilent Technologies
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Eurofins Scientific S.E.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. F. Hoffmann-La Roche Ltd.
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Illumina, Inc.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Myriad Genetics
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Oxford Nanopore Technologies Ltd.
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Pacific Bioscience
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Perkin Elmer
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Qiagen N.V.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Thermo Fisher Scientific
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제